222 related articles for article (PubMed ID: 1645779)
1. Mapping of a neutralizing antigenic site of Coxsackievirus B4 by construction of an antigen chimera.
Reimann BY; Zell R; Kandolf R
J Virol; 1991 Jul; 65(7):3475-80. PubMed ID: 1645779
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the N-terminal part of the neutralizing antigenic site I of coxsackievirus B4 by mutation analysis of antigen chimeras.
McPhee F; Zell R; Reimann BY; Hofschneider PH; Kandolf R
Virus Res; 1994 Nov; 34(2):139-51. PubMed ID: 7531922
[TBL] [Abstract][Full Text] [Related]
3. Expression of an antigenic adenovirus epitope in a group B coxsackievirus.
Höfling K; Tracy S; Chapman N; Kim KS; Smith Leser J
J Virol; 2000 May; 74(10):4570-8. PubMed ID: 10775593
[TBL] [Abstract][Full Text] [Related]
4. Complete nucleotide sequence of infectious Coxsackievirus B3 cDNA: two initial 5' uridine residues are regained during plus-strand RNA synthesis.
Klump WM; Bergmann I; Müller BC; Ameis D; Kandolf R
J Virol; 1990 Apr; 64(4):1573-83. PubMed ID: 2157045
[TBL] [Abstract][Full Text] [Related]
5. A point mutation in VP1 of coxsackievirus B4 alters antigenicity.
Halim S; Ramsingh AI
Virology; 2000 Mar; 269(1):86-94. PubMed ID: 10725201
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a foreign peptide expressed within a capsid protein of an attenuated coxsackievirus.
Halim SS; Ostrowski SE; Lee WT; Ramsingh AI
Vaccine; 2000 Nov; 19(7-8):958-65. PubMed ID: 11115722
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and antigenicity of chimeric picornaviruses which express hepatitis A virus (HAV) peptide sequences: evidence for a neutralization domain near the amino terminus of VP1 of HAV.
Lemon SM; Barclay W; Ferguson M; Murphy P; Jing L; Burke K; Wood D; Katrak K; Sangar D; Minor PD
Virology; 1992 May; 188(1):285-95. PubMed ID: 1314456
[TBL] [Abstract][Full Text] [Related]
8. An infectious cDNA copy of the genome of a non-cardiovirulent coxsackievirus B3 strain: its complete sequence analysis and comparison to the genomes of cardiovirulent coxsackieviruses.
Chapman NM; Tu Z; Tracy S; Gauntt CJ
Arch Virol; 1994; 135(1-2):115-30. PubMed ID: 8198437
[TBL] [Abstract][Full Text] [Related]
9. Requirements for RNA replication of a poliovirus replicon by coxsackievirus B3 RNA polymerase.
Bell YC; Semler BL; Ehrenfeld E
J Virol; 1999 Nov; 73(11):9413-21. PubMed ID: 10516050
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing activity induced by the attenuated coxsackievirus B3 Sabin3-like strain against CVB3 infection.
Jrad-Battikh N; Souii A; Oueslati L; Aouni M; Hober D; Gharbi J; Ben M'hadheb-Gharbi M
Curr Microbiol; 2014 Apr; 68(4):503-9. PubMed ID: 24322405
[TBL] [Abstract][Full Text] [Related]
11. Generation of an infectious cDNA of a highly cardiovirulent coxsackievirus B3(CVB3m) and comparison to other infectious CVB3 cDNAs.
Lee C; Maull E; Chapman N; Tracy S; Wood J; Gauntt C
Virus Res; 1997 Aug; 50(2):225-35. PubMed ID: 9282787
[TBL] [Abstract][Full Text] [Related]
12. Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon.
Chehadeh W; Lobert PE; Sauter P; Goffard A; Lucas B; Weill J; Vantyghem MC; Alm G; Pigny P; Hober D
J Virol; 2005 Nov; 79(22):13882-91. PubMed ID: 16254324
[TBL] [Abstract][Full Text] [Related]
13. Identification of Immunogenic Epitopes That Permit the Detection of Antigen-Specific T Cell Responses in Multiple Serotypes of Group B Coxsackievirus Infections.
Lasrado N; Gangaplara A; Arumugam R; Massilamany C; Pokal S; Zhou Y; Xiang SH; Steffen D; Reddy J
Viruses; 2020 Mar; 12(3):. PubMed ID: 32245257
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of an aphthovirus chimera of the glycoprotein of vesicular stomatitis virus.
Grigera PR; Garcia-Briones M; Periolo O; la Torre JL; Wagner RR
J Virol; 1996 Dec; 70(12):8492-501. PubMed ID: 8970972
[TBL] [Abstract][Full Text] [Related]
15. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3.
Knowlton KU; Jeon ES; Berkley N; Wessely R; Huber S
J Virol; 1996 Nov; 70(11):7811-8. PubMed ID: 8892902
[TBL] [Abstract][Full Text] [Related]
16. Coxsackieviral proteins functionally recognize the polioviral cloverleaf structure of the 5'-NTR of a chimeric enterovirus RNA: influence of species-specific host cell factors on virus growth.
Zell R; Klingel K; Sauter M; Fortmüller U; Kandolf R
Virus Res; 1995 Dec; 39(2-3):87-103. PubMed ID: 8837877
[TBL] [Abstract][Full Text] [Related]
17. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5' nontranslated region.
Tu Z; Chapman NM; Hufnagel G; Tracy S; Romero JR; Barry WH; Zhao L; Currey K; Shapiro B
J Virol; 1995 Aug; 69(8):4607-18. PubMed ID: 7609025
[TBL] [Abstract][Full Text] [Related]
18. Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice.
Chapman NM; Kim KS; Tracy S; Jackson J; Höfling K; Leser JS; Malone J; Kolbeck P
J Virol; 2000 Sep; 74(17):7952-62. PubMed ID: 10933703
[TBL] [Abstract][Full Text] [Related]
19. Mt10-CVB3 Vaccine Virus Protects against CVB4 Infection by Inducing Cross-Reactive, Antigen-Specific Immune Responses.
Lasrado N; Arumugam R; Rasquinha MT; Sur M; Steffen D; Reddy J
Microorganisms; 2021 Nov; 9(11):. PubMed ID: 34835449
[TBL] [Abstract][Full Text] [Related]
20. Antigenic profile of African horse sickness virus serotype 4 VP5 and identification of a neutralizing epitope shared with bluetongue virus and epizootic hemorrhagic disease virus.
Martínez-Torrecuadrada JL; Langeveld JP; Venteo A; Sanz A; Dalsgaard K; Hamilton WD; Meloen RH; Casal JI
Virology; 1999 May; 257(2):449-59. PubMed ID: 10329555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
